Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes
Published inBone Marrow Transplantation, vol. 55, no. 3, p. 586-594
Publication date2020
Abstract
Keywords
- Epstein-Barr Virus Infections / drug therapy
- Hematopoietic Stem Cell Transplantation / adverse effects
- Herpesvirus 4, Human
- Humans
- Lymphoproliferative Disorders
- Neoplasm Recurrence, Local
- Retrospective Studies
- Rituximab / therapeutic use
Affiliation Not a UNIGE publication
Citation (ISO format)
STOCKER, Nicolas et al. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. In: Bone Marrow Transplantation, 2020, vol. 55, n° 3, p. 586–594. doi: 10.1038/s41409-019-0699-6
Main files (1)
Article (Published version)
Identifiers
- PID : unige:154539
- DOI : 10.1038/s41409-019-0699-6
- PMID : 31562397
Commercial URLhttps://www.nature.com/articles/s41409-019-0699-6
ISSN of the journal0268-3369